Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Antimalarial agents, particularly hydroxychloroquine, are frequently used drugs in rheumatology, particularly in rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE). A growing awareness of increased malignancies in these autoimmune rheumatic conditions has raised suspicions that drugs may alter cancer risk in such patients. In vitro, antimalarial agents have been invoked as potentially increasing1 or decreasing2 neoplastic processes in breast cancer cells. It has also been suggested that these drugs may decrease the in vitro activity of lymphocytic leukaemia cells.3 However, there exists no definitive literature to show any explicit effect of antimalarial agents on cancer risk in clinical populations.
We have examined malignancy risk after antimalarial drug exposures, using a case–control design nested within a population-based …
Financial support: Sasha Bernatsky is the recipient of career awards from the Canadian Institutes for Health Research (CIHR), Fonds de recherche en santé du Québec (FRSQ), Canadian Arthritis Network, and of support from the McGill University Research Institute and Faculty of Medicine. Ann Clarke is an FRSQ National Scholar. Samy Suissa is the recipient of the James McGill professorship and the CIHR distinguished investigator award.